SCHEMBL6504654

SCHEMBL6504654

Cc1nc(CCO)c(C)o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359441 0.81
SCHEMBL13566370 0.79
SCHEMBL12396957 0.78 FBP1 (0.36)
SCHEMBL9317078 0.77
SCHEMBL2616804 0.76 TLR8 (0.33)
SCHEMBL5558454 0.75 PPARG (0.38)
SCHEMBL7922725 0.75 KDM4E (0.33)
SCHEMBL5559452 0.75 PPARG (0.39)
SCHEMBL9411909 0.75
SCHEMBL27656202 0.74 ELANE (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11724987-B2 Compositions and methods of treating retinal disease ALDEYRA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
US-20180194733-A1 COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE NEURON SYSTEMS, INC. 2018-07-12 US disclosed
US-9896419-B2 Compositions and methods of treating retinal disease ALDEYRA THERAPEUTICS, INC. (US) 2018-02-20 US disclosed
US-20170320829-A1 COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE ALDEYRA THERAPEUTICS, INC. 2017-11-09 US disclosed
US-9650342-B2 Compositions and methods of treating retinal disease ALDEYRA THERAPEUTICS, INC. (US) 2017-05-16 US disclosed
US-20160168098-A1 COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) 2016-06-16 US disclosed
US-9364471-B2 Compositions and methods of treating retinal disease ALDEYRA THERAPEUTICS, INC. (US) 2016-06-14 US disclosed
US-9265759-B2 Compositions and methods of treating retinal disease ALDEYRA THERAPEUTICS, INC. (US) 2016-02-23 US disclosed
EP-2935256-A1 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION Bristol-Myers Squibb Company (US) 2015-10-28 EP disclosed
US-20150209333-A1 COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) 2015-07-30 US disclosed
US-20150209345-A1 COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) 2015-07-30 US disclosed
US-8940721-B2 Compositions and methods of treating retinal disease ALDEXA THERAPEUTICS, INC. (US) 2015-01-27 US disclosed
WO-2014098831-A1 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2014-06-26 WO disclosed
US-20110263645-A1 Compositions and Methods of Treating Retinal Disease NEURON SYSTEMS, INC. (US) 2011-10-27 US disclosed
WO-2005040127-A1 NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME LG LIFE SCIENCES LTD. (KR) 2005-05-06 WO disclosed
EP-0177353-B1 THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1990-04-11 EP disclosed
US-4725610-A TREATMENT OF HYPERLIPEMIA AND DIABETES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-02-16 US disclosed
EP-0177353-A2 Thiazolidinedione derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1986-04-09 EP disclosed